Genentech Drug Rituxan Helps Lymphocytic Leukemia Patients

October 8, 2008

Genentech has touted the results of a study focused on their drug Rituxan.  The drug has proven to be successful in slowing down the progression of lymphocytic leukemia.<br /> .....Washington (ChattahBox) – Genentech has touted the results of a study focused on their drug Rituxan.  The drug has proven to be successful in slowing down the progression of lymphocytic leukemia.

A late-stage trial was conducted on 552 patients who had no success with other treatments.

This study, called REACH, found that the drug was successful in improving survival rates of patients.

Rituxan, when combined with chemotherapy, was able to slow the progression of the disease over time.

The next step for Genentech is to figure out when they want to move foward to try to get drug approval from the FDA.


Comments

Got something to say? **Please Note** - Comments may be edited for clarity or obscenity, and all comments are published at the discretion of ChattahBox.com - Comments are the opinions of the individuals leaving them, and not of ChattahBox.com or its partners. - Please do not spam or submit comments that use copyright materials, hearsay or are based on reports where the supposed fact or quote is not a matter of public knowledge are also not permitted.